Research, News, & Links

Scientific Research

NMDAR inhibition-independent antidepressant actions of ketamine metabolites (PDF)

A Double-Blind, Randomized, Placebo-Controlled, Dose-Frequency Study of Intravenous Ketamine in Patients With Treatment-Resistant Depression.

Efficacy of Intravenous Ketamine for Treatment of Chronic Posttraumatic Stress Disorder.

Randomized controlled crossover trial of ketamine in obsessive-compulsive disorder: proof-of-concept.

Antidepressant Efficacy of Ketamine in Treatment-Resistant Major Depression: A Two-Site Randomized Controlled Trial

Rapid and Longer-Term Antidepressant Effects of Repeated Ketamine Infusions in Treatment-Resistant Major Depression

Synaptic Dysfunction in Depression: Potential Therapeutic Targets

Safety and Efficacy of Repeated-Dose Intravenous Ketamine for Treatment-Resistant Depression

Glutamate NMDA receptor antagonists rapidly reverse behavioral and synaptic deficits caused by chronic stress exposure

A Randomized Add-on Trial of an N-methyl-D-aspartate Antagonist in Treatment-Resistant Bipolar Depression

Maintenance Ketamine Treatment Produces Long-term Recovery from Depression

NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses

A Randomized Trial of an N-methyl-D-aspartate Antagonist in Treatment-Resistant Major Depression

Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial

Ketamine as a novel antidepressant: from synapse to behavior

Serial infusions of low-dose ketamine for major depression (abstract)

Neurobiological advances identify novel antidepressant targets

The role of AMPA receptor modulation in the treatment of neuropsychiatric diseases

Synaptic function in depression: potential therapeutic targets

Rapid and longer-term anti-depressant effects of repeated ketamine infusions in treatment-resitant major depression

Efficacy of Intravenous Ketamine for Treatment of Chronic Posttraumatic Stress Disorder

A neurotrophic hypothesis of depression: role of synaptogenesis in the actions of NMDA receptor antagonists

NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses

Signaling Pathways Underlying the Rapid Antidepressant Actions of Ketamine

Antidepressant effects of ketamine: mechanisms underlying fast-acting novel antidepressants

In the News

Bloomberg (2015)  http://www.bloomberg.com/graphics/2015-ketamine-depression-treatment/

NPR (2015)  http://www.npr.org/sections/health-shots/2015/09/28/443203592/club-drug-ketamine-gains-traction-as-a-treatment-for-depression

Nature (2015)  http://www.nature.com/news/rave-drug-holds-promise-for-treating-depression-fast-1.16664

VICE News (2015)  https://www.vice.com/read/i-used-ketamine-to-treat-my-depression-122

NY Times (2014)  http://www.nytimes.com/2014/12/10/business/special-k-a-hallucinogen-raises-hopes-and-concerns-as-a-treatment-for-depression.html?_r=0

Scientific American (2013)  http://www.scientificamerican.com/article/is-ketamine-next-big-depression-drug/

Time (2013)  http://healthland.time.com/2013/05/22/club-drug-ketamine-lifts-depression-in-hours/

Psychology Today (2016)  A New Medication on the Horizon for Depression

Neurology Advisor (2016)  Ketamine May Be Effective in Major Depression

Psychiatry Advisor (2016)  May Provide Lasting Relief From Depression

PRNewswire (2016) New Study Shows Ketamine May Regenerate Brain Cells, Relieving Depression with Lasting Benefit

New York Magazine (2016)  What It’s Like to Have Your Severe Depression Treated With a Hallucinogenic Drug

Nature.com    Rave drug holds promise for treating depression fast

Economist.comNovel drugs for depression

NPR.com    Ketamine Relieves Depression By Restoring Brain Connections

National Institutes of Mental Health    Rapid Antidepressant Works by Boosting Brain’s Connections

CurrentPsychiatry.com    The future of ketamine in psychiatry

PsychiatricNews.com     Ketamine-Induced Optimism: New Hope for the Development of Rapid-Acting Antidepressants

TheAtlantic.com    ‘The Biggest Breakthrough in Depression Research’ in 50 Years Is … Ketamine?

J&J Press Release   Esketamine Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for Major Depressive Disorder with Imminent Risk for Suicide

CNN.com   Party drug ketamine closer to approval for depression

Nature.com   How club drug ketamine fights depression

NPR.com   Depression Treatments Inspired By Club Drug Move Ahead In Tests